The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Simply SELL THE COMPANY. JOB DONE. FINALLY!!!
Too much gravy left on this train to sell just now. Milk a year or two more salary first. Just keep your vision on the coming disruptive revolution Twix!
I'm expecting a few partners to be announced with this new step change going forward.
If Ranger was the first or second great hope I'd be on-board. Not when the 5th or 6th+ over many years looking at how we were kept invested before and what happened. The BOD wanted to rescue their credibility but I just feel I'd settle for 15p+ now as so little has EVER gone as expectation indicated. I'm cynical. There's always a reason for delay or disappointment. Maybe Ranger is the ONE. I expect we will find out as no sale likely. I'd prefer 15p+ after pumped and bidding war could be more
Twix, who knows, they might be looking to prove up Ranger a bit more ,then sell?
Yup, who knows.
I doubt it though. I think a sale is the plan but years off. IdI like it this year meaning actively in play working towards it today. Alas, it's not plan A for the BOD unfortunately. Aimho
be pointless selling now if they reckon they are on the cusp of disruptive tech . Just need to prove it now, and if it's as good as they say, then there will be more than one interested party I feel. It's good to hear independents like Labcorp, Laval uni etc confirming that Ranger is indeed very good.
I think the summer was mentioned, not long to wait then?
When you come out with things like 'disruptive' and 'revolution' then it had better be bloody good! Does anyone know exactly who and how this 'disrupts'? Is it Illumina, TF and will it disrupt their expensive machinery sales. Is it Streck tubes, where the EDTA tubes will win out, or maybe both?
Not sure myself tbh. Does Ranger need to work with Illumina machines or can it work independently. If it doesn't need Illumina then that's why it's disruptive, in a mahooosive way too.
so how and who will it disrupt? What is the 'revolution' game changer exactly?
apart from the obvious cost saving on the tubes !
It's more sensitive and uses smaller samples.
Google, Theranons !!! Haha
Theranos, sorry.
not sure what your point in other than you think Ranger is all a fraud!?
Just joking, brilliant story that's all.
But on the other hand you can see why people don't just jump into these things.
Needs some time that's all.
Did you see the CMD presentation? I think there is enough evidence there to show it's real and works according to the likes of Labcorp and a few very credible uni's.. No problems on that score !
agreed! cost savings will be the key, however they totally converted one lab onto Ygen's systems not knowing about the cost savings at the time. Just happy to get the better accuracy. So that says a lot knowing customers will adopt just for the accuracy alone. So the key disruptors are;
1; Better accuracy
2; smaller blood sample needed
3; much cheaper EDTA tubes (needs only one , not two Streck tubes)
Any more anyone can think of?
I think that's a bigger consideration than you think Frankie. After all it's why labs give out two tubes to start with. If plenty of labs start to adopt the EDTA then Streck tube manufacturers won't be very happy I guess.